<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="192977">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580047</url>
  </required_header>
  <id_info>
    <org_study_id>437-02-FB</org_study_id>
    <nct_id>NCT00580047</nct_id>
  </id_info>
  <brief_title>Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants</brief_title>
  <official_title>Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to look at the effect of different bone treatment plans on bone loss
      after kidney or kidney/pancreas transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims are to determine baseline bone mineral density (BMD) in kidney and kidney/pancreas
      transplant patients who will be randomized to weekly alendronate, annual zoledronic acid
      infusions or placebo (calcium with Vitamin D). These patients will be followed for two years
      with annual bone density testing as well as biochemical markers. A secondary aim is to
      evaluate compliance and tolerability of taking annual intravenous zoledronic acid versus
      weekly alendronate in the transplant recipient.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in Posterior Anterior (PA) spine bone density from baseline to 24 months post transplant</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in PA spine bone density from baseline to 12 months and percent change in total hip bone density from baseline to 24 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance will be quantified in the alendronate and placebo groups as the percentage of pills distributed that were taken. The occurence of side effects will be summarized using descriptive statistics and compared among the treatment groups.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zoledronic Acid 4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate 70mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcium 1200mg Vitamin D 800IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>4mg IV Annually</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium and Vitamin D</intervention_name>
    <description>1200 mg Calcium 800 International Units Vitamin D</description>
    <arm_group_label>3</arm_group_label>
    <other_name>calcium citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>70mg weekly</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Transplant patients who have had a kidney or kidney/pancreas transplant in the last
             150 days with adequate kidney function as defined by a calculated creatine clearance
             of 35ml/min or more and serum creatinine less than 3.0

        Exclusion Criteria:

          -  Dual X-ray Absorptiometry (DXA) T-score at the spine or hip of -3 or lower

          -  History of more than one vertebral or non-vertebral fracture in the past two years

          -  Abnormalities of the esophagus which delay esophageal emptying

          -  Inability to stay upright for 30 minutes

          -  Pregnant, nursing women or women not using an effective form of birth control

          -  Hypocalcemia

          -  Hypercalcemia

          -  Calculated creatinine clearance of &lt;35 ml/min or serum creatinine &gt; 3.0

          -  Patients already treated with bisphosphonates within the past one year

          -  Patients unable to undergo DXA

          -  Patients with cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Mack-Shipman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Lynn Mack, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>bone density</keyword>
  <keyword>osteopenia</keyword>
  <keyword>transplant</keyword>
  <keyword>zoledronic acid</keyword>
  <keyword>alendronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
